CHRS (Coherus Oncology, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CHRS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-09 | Rita A Karachun | Director | A | — | — |
| 2026-06-09 | Michael Lee Ryan | Director | A | — | — |
| 2026-06-09 | Lee Nisley Newcomer | Director | A | — | — |
| 2026-06-09 | Jill O'Donnell-Tormey | Director | A | — | — |
| 2026-06-09 | Charles W. Newton | Director | A | — | — |
| 2026-06-09 | Mats Wahlstrom | Director | A | — | — |
| 2026-06-09 | Ali J. Satvat | Director | A | — | — |
| 2026-06-02 | Bryan J McMichael | Chief Financial Officer | MIXED | — | — |
| 2026-06-02 | Dennis M Lanfear | President & CEO | MIXED | — | — |
| 2026-01-26 | Bryan J McMichael | Chief Financial Officer | A | — | — |
| 2026-01-26 | Dennis M Lanfear | President & CEO | A | — | — |
| 2026-01-22 | Bryan J McMichael | Chief Financial Officer | F | — | — |
| 2026-01-22 | Dennis M Lanfear | President & CEO | F | — | — |
| 2025-06-13 | Georgia Erbez | Director | A | — | — |
| 2025-06-13 | Michael Lee Ryan | Director | A | — | — |
| 2025-06-13 | Charles W. Newton | Director | A | — | — |
| 2025-06-13 | Rita A Karachun | Director | A | — | — |
| 2025-06-13 | Lee Nisley Newcomer | Director | A | — | — |
| 2025-06-13 | Ali J. Satvat | Director | A | — | — |
| 2025-06-13 | Mats Wahlstrom | Director | A | — | — |
| 2025-06-13 | Jill O'Donnell-Tormey | Director | A | — | — |
| 2025-05-28 | Mats Wahlstrom | Director | Sell | — | — |
| 2025-05-09 | Dennis M Lanfear | President & CEO | A | — | — |
| 2025-05-09 | Bryan J McMichael | Chief Financial Officer | A | — | — |
| 2025-01-22 | Paul Reider | Chief Commercial Officer | F | — | — |
| 2025-01-22 | Bryan J McMichael | Chief Financial Officer | F | — | — |
| 2025-01-22 | Dennis M Lanfear | President & CEO | F | — | — |
| 2025-01-14 | Dennis M Lanfear | President & CEO | A | — | — |
| 2025-01-10 | Bryan J McMichael | Chief Financial Officer | F | — | — |
| 2025-01-07 | Dennis M Lanfear | President & CEO | F | — | — |
| 2025-01-07 | Bryan J McMichael | Chief Financial Officer | A | — | — |
| 2025-01-07 | Paul Reider | Chief Commercial Officer | F | — | — |
| 2024-12-17 | Paul Reider | Chief Commercial Officer | F | — | — |
| 2024-08-09 | Bryan J McMichael | Chief Financial Officer | A | — | — |
| 2024-07-24 | Dennis M Lanfear | President & CEO | A | — | — |
| 2024-07-24 | Paul Reider | Chief Commercial Officer | A | — | — |
| 2024-06-05 | Jill O'Donnell-Tormey | Director | A | — | — |
| 2024-06-05 | Rita A Karachun | Director | A | — | — |
| 2024-06-05 | Michael Lee Ryan | Director | A | — | — |
| 2024-06-05 | Charles W. Newton | Director | A | — | — |
| 2024-06-05 | Mats Wahlstrom | Director | A | — | — |
| 2024-06-05 | KIMBERLY JO TZOUMAKAS | Director | A | — | — |
| 2024-06-05 | Lee Nisley Newcomer | Director | A | — | — |
| 2024-06-05 | Georgia Erbez | Director | A | — | — |
| 2024-06-05 | MARK STOLPER | Director | A | — | — |
| 2024-02-22 | Georgia Erbez | Director | A | — | — |
| 2024-02-15 | Mats Wahlstrom | Director | G | — | — |
| 2024-02-05 | Mats Wahlstrom | Director | M | — | — |
| 2024-01-23 | Paul Reider | Chief Commercial Officer | F | — | — |
| 2024-01-23 | Bryan J McMichael | See Remarks | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | — | 3,042,019 | — |
| — | — | 2,867,426 | — |
| — | 10%+ Owner | 2,499,499 | — |
| — | President & CEO | 1,135,200 | — |
| — | 10%+ Owner | 361,594 | — |
| — | Chief Scientific Officer | 350,624 | — |
| — | Director | 298,422 | — |
| — | Chief Financial Officer | 133,736 | — |
| — | Chief Operating Officer | 124,790 | — |
| — | Chief Scientific Officer | 116,361 | — |
| — | Chief Commercial Officer | 82,069 | — |
| — | Chief Financial Officer | 75,305 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CHRS quote page; the site-wide leaderboard is on the insider transactions hub.